Omnicell, Inc. (OMCL) stock analysis

Healthcare · Health Information Services

From the 10-K filed 2026-02-26

How it makes money

It generates $636 million in annual recurring revenue from a mix of technical services, medication adherence consumables, and subscription-based expert pharmacy services.

Omnicell earns through a dual-revenue model: one-time sales of hardware like the Titan XT automated dispensing systems, and recurring streams that include technical support and proprietary blister packaging consumables.

Its highest-growth area is SaaS and Expert Services, where it manages the complex 340B federal drug pricing program and provides the personnel to operate automated IV compounding and central pharmacy robots for health systems.

What protects it: the moat

The OmniSphere intelligence ecosystem unifies hardware and software into a platform layer that tracks medications to prevent diversion across thousands of healthcare facilities.

The business is protected by high switching costs integrated into clinical workflows. Because its automated cabinets handle controlled substances and must comply with the Drug Supply Chain Security Act (DSCSA) interoperability deadlines, removing the hardware would disrupt the entire medication supply chain.

Management claims its 340B Optimization and Specialty Pharmacy services further lock in customers by managing audit readiness for a federal program on track to exceed $200 billion in gross sales.

What growth costs

It maintains 3,580 employees to support long sales cycles and nearshores manufacturing to mitigate fluctuating tariffs on components from China and Mexico.

Growth depends on heavy R&D to advance the "Autonomous Pharmacy" vision and capital-intensive sales efforts. Unlike a pure software business, Omnicell must dual-source physical components and manage inventory for its medication adherence packaging.

The transition toward "as-a-service" models requires significant upfront investment in expert personnel and implementation teams who operate the machinery on-site before long-term subscription revenue is fully realized.

What could damage it

A $910 billion reduction in Medicaid spending via the One Big Beautiful Bill Act could compress hospital margins and halt capital equipment investments.

The primary threat is a liquidity crisis within the hospital sector. Because the core hardware represents a "sizable initial capital expenditure," fiscal headwinds from health policy changes or rising labor costs can cause customers to defer or cancel modernization projects.

If health systems delay the adoption of Titan XT or XTExtend console swaps due to these budget constraints, the company's product bookings fall, stalling the expansion of the higher-margin recurring revenue base.

About Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Other companies in Health Information Services